, Volume 110, Issue 2, pp 87–91 | Cite as

Effects of iron and desferrioxamine on Rhizopus infection

  • Fumihiko Abe
  • Hayashi Inaba
  • Tadashi Katoh
  • Masao Hotchi


To investigate the association among iron, desferrioxamine, and a Rhizopus infection, the influence of iron and/or desferrioxamine on experimental mucormycosis in mice was examined. All mice pretreated with iron, desferrioxamine, or a combination of iron and desferrioxamine died within 5 days after the inoculation of R. oryzae. In the mice fungal lesions were observed in the brain which resembled human cerebral mucormycosis. By contrast, the mortality in the control mice with R. oryzae was 20% through the 3-week experimental period. Therefore, it was demonstrated that iron as well as desferrioxamine administration markedly promotes the growth of R. oryzae. The increased susceptibility to R. oryzae was considered to be due to increased serum iron in the animals pretreated with iron only; however, pretreatment with desferrioxamine did not affect the amount of serum ion. Thus, the data suggest that desferrioxamine acts as a siderophore to R. oryzae and exerts an adverse effect on mucormycosis. This study has shown that the presence of iron and desferrioxamine enhances the virulence and pathogenicity of R. oryzae by serving as a growth factor.

Key words

desferrioxamine iron iron overload mucormycosis Rhizopus oryzae 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abe F, Tateyama M, Shibuya H, Azumi N, Ommura Y. Experimental candidiasis in iron overload. Mycopathologia 1985; 89: 59–63.Google Scholar
  2. 2.
    Boelaert JR, van Roost GF, Vergauwe PL, Verbanck JJ, de Vroey CH, Segaert MF. The role of desferrioxamine in dialysis-associated mucormycosis; report of three cases and review of the literature. Clin Nephrol 1988; 29: 261–6.Google Scholar
  3. 3.
    Chiesa C, Pacifico L, Renzulli F, Midulla M, Garlaschi L. Yersinia hepatic abscesses and iron overload. JAMA 1987; 257: 3230–31.Google Scholar
  4. 4.
    Eiser AR, Slifkin RF, Neff MS. Intestinal mucormycosis in hemodyalysis patients following deferoxamine. Am J Kidney Dis 1987; 10: 71–3.Google Scholar
  5. 5.
    Goodill JJ, Abuelo JG. Mucormycosis; a new risk of deferoxamine therapy in dialysis patients with aluminum or iron overload? N Engl J Med 1987; 317: 54.Google Scholar
  6. 6.
    Holzberg M, Artis WM. Hydroxamate siderophore production by opportunistic and systemic fungal pathogens. Infect Immun 1983; 40: 1134–39.Google Scholar
  7. 7.
    Modell B. Advances in the use of iron-chelating agents for the treatment of iron overload. Prog Hematol 1979; 11: 267–312.Google Scholar
  8. 8.
    Neilands JB. Microbial iron compounds. Ann Rev Biochem 1981; 50: 715–31.Google Scholar
  9. 9.
    Robins-Browne RM, Prpic JK. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Infect Immun 1985; 47: 774–9.Google Scholar
  10. 10.
    Schwarz JN, Donnelly EH, Klintworth GK. Ocular and orbital phycomycosis. Surv Ophthalmol 1977; 22: 3–28.Google Scholar
  11. 11.
    Veis JH, Contiguglia R, Klein M, Mishell J, Alfrey AC, Shapiro JI. Mucormycosis in deferoxamine-treated patients on dialysis. Ann Intern Med 1987; 107: 258.Google Scholar
  12. 12.
    Weinberg ED. Iron and infection. Microbiol Rev 1978; 42: 45–66.Google Scholar
  13. 13.
    Windus DW, Stokes TJ, Julian BA, Fenves AZ. Fatal Rhizopus infections in hemodialysis patients receiving deferoxamine. Ann Intern Med 1987; 107: 678–80.Google Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Fumihiko Abe
    • 1
  • Hayashi Inaba
    • 1
  • Tadashi Katoh
    • 1
  • Masao Hotchi
    • 1
  1. 1.Department of PathologyShinshu University School of MedicineMatsumotoJapan

Personalised recommendations